What guidance did Lexicon Pharmaceuticals's management provide for the next earnings period?

What does Lexicon Pharmaceuticals do and what are its main business segments?

What factors drove the changes in Lexicon Pharmaceuticals's revenue and profit?

Did Lexicon Pharmaceuticals beat or miss consensus estimates last quarter?

What were the key takeaways from Lexicon Pharmaceuticals's earnings call?

What is the revenue and EPS growth rate for Lexicon Pharmaceuticals year over year?

What were the key takeaways from Lexicon Pharmaceuticals’s earnings call?

What is Lexicon Pharmaceuticals's latest dividend and current dividend yield?

- **HCM Trial Momentum:** Sotagliflozin Phase III >50% enrolled, targeting mid-2026 completion with potential 2027 data.
- **T1D Regulatory Path:** Zynquista NDA resubmission expected in 2026 with STENO1 data; first oral therapy for T1D if approved.
- **Partnership Progress:** Pilavapadin Phase III discussions advanced; LX9851 on track for $20M milestone in 2026.
- **Financial Strength:** $200M+ cash post-capital raise; 2026 expenses guided to $100-110M with disciplined spending.

**【CEO Summary Section】**
- Lexicon achieved significant progress in 2025, entering 2026 with momentum across its cardiometabolic and chronic pain portfolios.
- Key programs include sotagliflozin (HCM and type 1 diabetes), LX9851 (obesity), and pilavapadin (DPNP). Upcoming milestones include HCM Phase III enrollment completion by mid-2026, Zynquista NDA resubmission in 2026, and pilavapadin Phase III discussions with partners.
- Financially strong with $125.2M in cash as of Q4 2025, plus $100M from recent capital raise, supporting disciplined expense management.

**【CMO Program Updates】**
- **Sotagliflozin (HCM):** SONATA-HCM Phase III trial >50% enrolled, targeting mid-2026 completion. Dual SGLT1/SGLT2 inhibition offers unique myocardial benefits; STENO1 study supports T1D NDA resubmission potential in 2026.
- **Pilavapadin (DPNP):** Phase III-ready with successful FDA end-of-Phase II meeting; partner discussions ongoing for 12-week Phase III studies.
- **LX9851 (Obesity):** Novo Nordisk driving development post-IND handoff; $10M milestone achieved in Q1 2026, with potential for $20M more this year.

**【CFO Financial Summary】**
- **Q4 2025 Results:** Total revenue $5.5M (license: $4.3M, INPEFA: $1.1M). R&D expenses down 54% YoY to $11.3M; SG&A down 76% YoY to $8.8M.
- **2026 Guidance:** Operating expenses $100-110M (R&D: $63-68M, SG&A: $37-42M). Cash position strengthened to >$200M post-capital raise.

**【Q&A Highlights】**
- **Zynquista (T1D):** STENO1 study tracking well for DKA rate <3.5/100 patient-years; resubmission and potential approval in 2026.
- **Pilavapadin Partnership:** FDA alignment on Phase III design accelerates partner discussions; no plans to self-fund Phase III.
- **LX9851 Development:** Novo exploring oral combination therapies; Lexicon focused on near-term milestones ($20M potential 2026).

Lexicon Pharmaceuticals, Inc. (LXRX) Q4 2025 Earnings Call Transcript

- **Pipeline Momentum**: Pilobafidin phase 2 data support phase 3 readiness; LX9851 IND filing imminent; Sonata HCM trial on track. 
- **Financial Strength**: Q3 2025 revenue up 700% YoY; operating expenses reduced by 78% since 2024. 
- **Strategic Focus**: Transitioning to R&D-driven model with disciplined capital allocation; exploring innovative commercial strategies. 
- **Regulatory Catalysts**: FDA feedback on Zingquista expected Q4; sotagliflozin presentations at AHA and HCM Society highlight broad cardiometabolic potential.

**【CEO Opening Remarks】**
- Lexicon achieved significant progress in 2025, including advancing pilobafidin toward phase 3, submitting an IND for LX9851, and accelerating recruitment in the Sonata HCM trial. 
- The company repositioned as an R&D-focused organization, reducing operating expenses by $39.1 million year-over-year while maintaining investment in high-value programs. 
- Empefa is transitioning from a break-even business to a growth driver in 2026, supported by a virtual sales system. 
- Legislative momentum in chronic pain management, including the Relief of Chronic Pain Act, aligns with pilobafidin's potential as a non-opioid alternative.

**【CMO Pipeline Update】**
- **Pilobafidin**: Phase 2 data showed a 2-point reduction in ADPS with 10mg dose, robust tolerability, and no cardiac signals. An end-of-phase 2 meeting with FDA is scheduled for late 2025. 
- **LX9851**: IND-enabling studies completed; Novo Nordisk may trigger $30M milestones upon IND filing. 
- **Sotagliflozin**: Sonata HCM trial (n=250 per subgroup) achieved 130+ site activations across 20 countries. Upcoming AHA and HCM Society presentations will highlight sotagliflozin's impact on cardiac remodeling and HFpEF. 
- **Zingquista**: FDA feedback expected by end-2025; potential resubmission in 2026 based on Steno trial DKA data.

**【CFO Financial Summary】**
- Q3 2025 revenue: $14.2M (vs. $1.8M in 2024), driven by $13.2M from Novo Nordisk agreement. 
- R&D expenses: $18.8M (down 27% YoY); SG&A: $7.6M (down 81% YoY). 
- Net loss: $12.8M; cash balance: $145M. 
- Full-year 2025 guidance: $105-115M operating expenses, with R&D at $70-75M.

**【Q&A Highlights】**
- **Zingquista Regulatory Path**: FDA expects written feedback by end-2025; potential 6-month review clock for resubmission. 
- **Pilobafidin Partnerships**: Discussions ongoing with high-quality partners; end-of-phase 2 meeting will inform partnership strategy. 
- **Sotagliflozin Positioning**: Targeted as first-line therapy for HCM due to ease of use and lack of REMS; differentiated from CMIs with broad cardiometabolic profile. 
- **Commercial Strategy**: Exploring virtual, hybrid, or co-promotion models for Zingquista; leveraging patient advocacy networks for market access.

Lexicon Pharmaceuticals, Inc. (LXRX) Q3 2025 Earnings Call Transcript

- **Pipeline Momentum**: All lead assets (pilavapadin, sotagliflozin, LX9851) advancing on track, with Phase III trials enrolling globally.
- **Financial Strength**: Q2 2025 revenue up 1,700% YoY to $28.9M, driven by Novo Nordisk license; operating expenses reduced 58% YoY to $105-115M.
- **Strategic Partnerships**: Collaborations with Novo Nordisk (obesity) and Viatris (sotagliflozin) accelerate global reach; pilavapadin partner discussions active.
- **Clinical Differentiation**: Sotagliflozin uniquely targets both obstructive and nonobstructive HCM; pilavapadin validated as 10mg dose for Phase III.
- **Cost Efficiency**: R&D expenses down 11% YoY; SG&A reduced 76% YoY through strategic repositioning.

**【CEO Opening Remarks】**
- Lexicon has successfully transitioned to an R&D-focused company, with all lead programs on track. Key updates include:
  - Pilavapadin Phase IIb secondary analysis completed, supporting 10mg dose for late-stage development.
  - LX9851 IND-enabling studies expected to complete in 2025, with Novo Nordisk as licensee.
  - Sotagliflozin Phase III SONATA trial in HCM advancing globally, with 100+ sites initiated.
  - Viatris expanding sotagliflozin's reach in non-U.S./EU markets, with UAE approval secured.

**【CMO Pipeline Update】**
- **Pilavapadin**: 
  - Phase IIb PROGRESS study shows 10mg dose reduces pain in diabetic neuropathy (DPNP), validated by scientific advisory board.
  - Preclinical data supports broad applicability across spasticity, spina bifida, and other indications.
  - 600+ patients treated with strong safety profile, patent protection through 2040.
- **Sotagliflozin in HCM**: 
  - SONATA trial enrolling globally, targeting 130 sites by Q3 2025.
  - Investigator-initiated studies (SOTA-CROSS, SOTA-P-CARDIA) expected to report in late 2025/2026.
  - Unique dual SGLT1/SGLT2 mechanism addresses both obstructive and nonobstructive HCM.
- **LX9851**: 
  - IND-enabling studies progressing, targeting obesity and metabolic disorders.
  - Collaboration with Novo Nordisk to explore combination therapies.

**【CFO Financial Update】**
- Q2 2025 Revenue: $28.9M (vs. $1.6M in 2024), driven by $27.5M from Novo Nordisk license.
- R&D Expenses: $15.7M (down 11% YoY), SG&A: $9.4M (down 76% YoY).
- Net Income: $3.3M (vs. -$53.4M in 2024), due to license revenue recognition.
- 2025 Guidance: Operating expenses reduced to $105-115M (from $135-145M), R&D: $70-75M.
- Cash Position: $168M as of Q2, down from $238M at year-end 2024.

**【Q&A Highlights】**
- **Pilavapadin Partnering**: End-of-Phase II meeting with FDA expected soon; discussions with potential partners progressing.
- **Sotagliflozin in HCM**: Enrollment benefits from lack of competing trials; nonobstructive HCM patients driving U.S. enrollment.
- **LX9851 Development**: Novo Nordisk plans Phase I studies post-IND; oral, once-daily formulation positions for combination therapies.
- **Pain Market Dynamics**: Vertex's VX-993 Phase II failure reinforces confidence in pilavapadin's novel AAK1 mechanism.
- **INPEFA Commercialization**: Viatris pursuing approvals in Canada, Australia, and Southeast Asia, complementing U.S. sales.


Lexicon Pharmaceuticals, Inc. (LXRX) Q2 2025 Earnings Call Transcript

- **$45M upfront win**: Novo deal slashes debt, extends cash to $194M, enabling Phase 3 for DPNP and HCM.
- **Pilavapadin progress**: 10mg dose shows 1.5-2x pain reduction, with Q3 data setting up 2025 Phase 3 start.
- **Sotagliflozin momentum**: 500-patient HCM trial enrolling globally, targeting both obstructive and non-obstructive subtypes.
- **Cost efficiency**: 64% SG&A cut slashes net loss 48% YoY to $25.3M, while R&D stays focused on late-stage assets.
- **Partnership power**: Viatris advancing ex-US sotagliflozin filings, Novo driving LX9851 development.

**【CEO Opening Remarks】**
- Announced exclusive license agreement with Novo Nordisk for LX9851, a first-in-class obesity treatment, securing $45M upfront payment and up to $1B in milestones plus royalties.
- Pilavapadin Phase 2B results: 10mg dose showed 1.5-2 point pain reduction vs placebo, with tolerability comparable to placebo. Full data expected Q3 for Phase 3 design.
- Financial restructuring: Reduced operating costs, used Novo payment to cut debt, and extended cash runway to $194.8M as of Q1.

**【CFO Financial Update】**
- Q1 2025 revenue: $1.1M (INPEFA sales), down 90% YoY due to reduced marketing.
- R&D expenses: $15.3M (+6% YoY) for Phase 3 trials in HCM and DPNP.
- SG&A: $11.6M (-64% YoY) due to strategic cost cuts.
- Net loss: $25.3M (-48% YoY), driven by lower expenses and one-time severance payments.
- 2025 guidance: Total expenses $135-145M (R&D: $100-105M, SG&A: $35-40M).

**【Business Updates】**
- Sotagliflozin (SONATA trial): 500-patient Phase 3 enrolling globally, targeting both obstructive and non-obstructive HCM. Viatris advancing ex-US regulatory filings (UAE, Saudi Arabia, Canada).
- LX9851: Novo leading IND submission and clinical development, with Lexicon supporting early-stage supply.
- Zynquista: FDA end-of-review meeting planned, with patient advocacy supporting T1D approval.

**【Q&A Highlights】**
- Pilavapadin Phase 3: Two parallel trials (US-only and global) targeting 300-350 patients/ arm. FDA feedback expected post-Q3 data release.
- Sotagliflozin in HCM:powered for overall KCCQ improvement, with subgroup analyses for obstructive vs non-obstructive. No additional endpoints needed beyond functionality.
- LX9851 development: Novo fully engaged in IND process, with Lexicon providing limited supply support.
- Financial flexibility: $194.8M cash runway supports Phase 3 readiness for DPNP and HCM trials.

Lexicon Pharmaceuticals, Inc. (LXRX) Q1 2025 Earnings Call Transcript

- **Pilavapadin Breakthrough**: 10mg dose shows 1.74 ADPS reduction vs. placebo in DPNP, advancing to Phase 3 with 12-week trials.
- **Sotagliflozin Expansion**: HCM Phase 3 study enrolling globally, targeting FDA filing in Q1 2027.
- **LX9851 Potential**: Obesity asset IND submission in 2025; preclinical data highlights weight loss and combination benefits.
- **Financial Stability**: $238M cash, 2025 expenses guided at $135M-$145M, reflecting cost-cutting and strategic focus.

**【CEO Summary Section】**
- **Pilavapadin Phase 2b Results**: The 10mg dose showed a 1.74 ADPS reduction vs. placebo, with improved tolerability compared to the 20mg/10mg regimen. PROGRESS data supports advancing the 10mg dose into Phase 3 trials for DPNP, targeting 12-week studies to achieve further separation from placebo.
- **Sotagliflozin in HCM**: The SONATA Phase 3 study is enrolling ~500 patients globally, with U.S. and ex-U.S. sites active. Regulatory filing for HCM is expected in Q1 2027, contingent on trial completion.
- **LX9851 Obesity Asset**: IND-enabling studies are on track for 2025 submission. Preclinical data shows weight loss and fat mass reduction in mice, with potential for monotherapy or combination with GLP-1 agonists. Partnership discussions are ongoing.
- **INPEFA Update**: U.S. promotion ceased due to market competition, but sotagliflozin remains available. Viatris leads ex-U.S. and ex-Europe development.

**【CFO Financial Commentary】**
- **Q4 2024 Financials**: Revenue of $26.6M (including $25M Viatris upfront), net loss of $33.8M. Full-year 2024 revenue $31.1M, net loss $200.4M.
- **Expense Management**: 2025 operating expenses projected at $135M-$145M, with R&D ($100M-$105M) and G&A ($35M-$40M). INPEFA-related costs reduced by eliminating U.S. sales force.
- **Cash Position**: $238M as of Q4 2024, up from $170M in 2023.

**【Q&A Highlights】**
- **LX9851 Development**: Phase 1 will assess weight loss, tolerability, and mechanism differentiation. Partnering decisions will depend on clinical data and strategic fit.
- **SONATA Enrollment**: 30 U.S. sites and 120 global sites targeting 500 patients. No restrictions on background therapies (e.g., CMIs).
- **Pilavapadin FDA Meeting**: End-of-Phase 2 meeting expected Q3 2025, with Phase 3启动计划在2025年底。
- **Sotagliflozin Commercialization**: U.S. commercialization for HCM planned; Viatris handles ex-U.S./Europe. HCM payer environment differs from heart failure due to lack of SGLT2 competition.

Actual										-0.63	0.71	-0.04	-0.15	-0.13	-0.16	-0.17	-0.16	-0.16	-0.13	-0.16	-0.17	-0.22	-0.21	-0.2	-0.2	-0.17	-0.18	-0.09	-0.07	0.01	-0.04	-0.04
Forecast										-0.6945	0.3671	-0.2766	-0.1574	-0.1597	-0.1776	-0.1828	-0.1657	-0.1611	-0.1401	-0.1339	-0.1793	-0.1747	-0.2147	-0.2172	-0.18	-0.177	-0.1628	-0.1273	-0.095	-0.075	-0.066	-0.069
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	+9.29%	+93.41%	+85.54%	+4.70%	+18.60%	+9.91%	+7.00%	+3.44%	+0.68%	+7.21%	-19.49%	+5.19%	-25.93%	+2.19%	+7.92%	-11.11%	+3.95%	-10.57%	+29.30%	+26.32%	+113.33%	+39.39%	+42.03%

Actual	--	--	--	--	--	--	--	--	--	8.00M	139.45M	199.00K	27.00K	234.00K	23.00K	14.00K	37.00K	35.00K	39.00K	28.00K	24.00K	317.00K	162.00K	702.00K	1.10M	1.65M	1.75M	26.55M	1.26M	28.87M	14.18M	5.49M
Forecast	--	--	--	--	--	--	--	--	--	7.78M	91.34M	66.67K	2.23M	13.50K	0	0	50.00K	100.00K	50.00K	50.00K	33.33K	66.67K	2.06M	1.25M	1.40M	3.44M	2.99M	6.48M	1.41M	4.87M	4.65M	3.14M
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	+2.79%	+52.68%	+198.50%	-98.79%	+1633.33%	0.00%	0.00%	-26.00%	-65.00%	-22.00%	-44.00%	-28.00%	+375.50%	-92.14%	-43.88%	-21.43%	-52.06%	-41.54%	+309.82%	-10.65%	+493.04%	+205.04%	+74.85%

LXRX

LXRX fundamentals

LXRX Q4 2025 Earnings

Earnings Call

You can ask Aime

LXRX

LXRX fundamentals

LXRX Q4 2025 Earnings

Earnings Call

LXRX Earnings Call Summary for Q4/20258:30 AM on Mar 5, 2026

LXRX Earnings Call Summary for Q3/20258:30 AM on Nov 6, 2025

LXRX Earnings Call Summary for Q2/20258:30 AM on Aug 6, 2025

LXRX Earnings Call Summary for Q1/20255:00 PM on May 13, 2025

LXRX Earnings Call Summary for Q4/20245:00 PM on Mar 6, 2025

You can ask Aime